Protavio Ltd

Excited to share that Protavio’s co-founder, Prof. Leonidas Alexopoulos, will present a live webinar, “Advancing early detection of colorectal cancer with novel blood-based protein biomarkers”, as part of this year’s Olink Proteomics Coffee Breaks series. When: December 10, 2025 | 5:00 AM (PST), 8:00 AM (EST), 2:00 PM (CET) How to attend: Register now → https://lnkd.in/dt9QcJvT In this 30-minute session, you’ll learn: - How Olink Explore and Explore HT enable large-scale, sensitive protein measurements to accelerate biomarker discovery for early cancer detection - Practical obstacles that arise in real-world biomarker discovery and strategies to mitigate them early - How to prioritise and select robust protein biomarkers for inclusion in in vitro diagnostic assays. #Protavio #BiomarkerDiscovery #Webinar #Olink

Είμαστε στην ευχάριστη θέση να ανακοινώσουμε ότι η Protavio γίνεται επίσημος αντιπρόσωπος της Olink Proteomics, μέρος της Thermo Fisher Scientific, σε Ελλάδα, Κύπρο και Μάλτα! Μια σημαντική συνεργασία που φέρνει την κορυφαία τεχνολογία affinity proteomics της Olink ακόμη πιο κοντά στην ερευνητική και διαγνωστική κοινότητα της Ελλάδας και της Κύπρου. Η Protavio, ένας από τους πρώτους παρόχους Olink Proteomics στην Ευρώπη, προσφέρει πλέον όλα τα προϊόντα Olink (Explore, Reveal, Target, Flex, Focus) και συμβάλλει με ένα ακόμη βήμα στην ενίσχυση της ελληνικής ερευνητικής κοινότητας με τεχνολογίες αιχμής για biomarker discovery και clinical translation. 📩 Επικοινωνήστε μαζί μας για να μάθετε περισσότερα. https://lnkd.in/dpNXuyeR #Protavio #Olink #Proteomics #Biotechnology #Innovation #Research #LifeSciences

Excited to share that Protavio Ltd’s co-founder, Prof. Leonidas Alexopoulos, will present a live webinar, “Advancing Early Detection of Colorectal Cancer with Blood-Based Protein Biomarkers”, as part of this year’s Olink Proteomics Coffee Breaks series. When: December 10, 2025 | 9:00 AM ET / 2:00 PM CET How to attend: Register now → https://hubs.la/Q03MJR5t0 In this 30-minute session, you’ll: ✔ ️  Discover how NGS-based proteomics uncovers novel blood-based biomarkers for early CRC and advanced adenoma detection, paving the way for more accurate cancer screening and better patient outcomes. ✔ ️ Learn how Olink Explore and Explore HT enable large-scale, sensitive protein measurements to accelerate oncology biomarker discovery. ✔ ️ Learn how to avoid pitfalls in the biomarker selection process. ✔ ️  Explore the promise of a non-invasive, routine blood test to transform cancer screening and improve adherence. #Protavio #Oncology #Webinar #OlinkEvents https://lnkd.in/dEkfcbe8

Protavio Ltd at 7th Advances in Circulating Tumor Cells Meeting (ACTC) Proud to have sponsored and joined the global ACTC community in Thessaloniki last week, with key themes the rising clinical momentum for liquid biopsy, the central role of quality and standards, and the power of cross-sector collaboration. Grateful to everyone who stopped by our stand and discussed early detection, minimal residual disease, therapy selection and longitudinal monitoring, precisely the settings where Protavio’s robust, scalable proteomic read-outs can complement genomic assays and help translate liquid-biopsy discoveries into patient impact. Read more: https://lnkd.in/d5d4bWci #LiquidBiopsy #CTCs #ctDNA #MRD #PrecisionOncology #Proteomics #ClinicalResearch #ACTC2025 #Protavio

Day 2 of BIO3 2025 Forum at Technopolis, Athens! Protavio is proud to be a sponsor of this exciting Biotechnology, Bioinformatics and Bioeconomy event, organized by BioInnovation Greece Greece, bringing together global leaders in biotech, healthcare and innovation. The forum (15–19 September) is a vibrant hub for collaboration, knowledge exchange, and exploring transformative ideas shaping the future of life sciences. Come connect with us to learn more about our cutting-edge multiplex proteomics technologies and explore the future of biotech together! 📅 Agenda: https://lnkd.in/e2JJ6jdd #BIO32025 #BioInnovation #Protavio #Multiplex #Proteomics

Population-scale proteomics is no longer theoretical, it’s happening now. Landmark initiatives like the UK Biobank Pharma Proteomics Project and the Regeneron Genetics Center are harnessing Olink Proteomics Explore HT to profile >5,400 proteins across hundreds of thousands of samples, opening unprecedented avenues for biomarker discovery and precision medicine. As a certified Olink Explore service provider, Protavio brings this same next-generation platform to your research. Whether you’re accelerating biomarker discovery or validating your results, our expert team and streamlined workflows turn proteomic complexity into actionable insight. 📰 Read the full article to see how Olink is transforming proteomics and how Protavio can help you harness this power and turn data into impact: https://lnkd.in/dF8PQ_cb #Proteomics #OlinkExploreHT #BiomarkerDiscovery #PrecisionMedicine #NextGenerationOmics #Protavio

Are you passionate about turning cutting-edge biotechnology into real-world breakthroughs? Join Protavio Ltd.’s expanding R&D team in Athens, Greece as our Lab Scientist and help us translate advanced proteomics into next‑generation in‑vitro diagnostic products. At Protavio, we’re on a mission to revolutionize healthcare through innovation in proteomics and biomarker discovery. If you’re detail‑driven, scientifically curious, and thrive in a fast‑paced, dynamic environment, we want to hear from you! Qualifications • Academic degree in Biology, Biochemistry, Pharmacology, Biomedical Engineering, or relevant fields • Excellent organizational, time management and problem-solving skills • Ability to effectively communicate and collaborate with cross-functional teams • A proven track record of excellence (e.g. good grades, awards, publications, strong recommendations) • Ability to contribute in multiple projects with competing priorities • Experience in proteomics, biomarker discovery, assay development, or ISO13485 quality management system is a plus ➡️ Ready to make an impact? Apply now and let us know how you envision contributing to our team: https://lnkd.in/dRDbFf7z

Calling all proteomics & multi‑omics researchers! Protavio is proud to be an Olink‑certified service provider, and we’re thrilled to share that Olink Proteomics has opened a Proteomics Grant, offering FREE analysis of 86 samples using Olink® Explore HT! With this platform, the winners will measure ~5,400 protein assays in just a few µl of each of their samples, with readout on NGS and high level data analysis also covered. 🗓️ Deadline: 8 September 2025, 23:00 CEST Four winners will be announced by Olink on 15 October 2025. 👉 How to apply: Submit a short (≤ 300 words) abstract describing how you’ll use high‑throughput proteomics to push your research forward. Click here to read more and apply: info.olink.com/grant As a certified service provider, Protavio’s team is here to help if you’d like advice on experimental design or technical requirements before you submit. #Proteomics #Olink #ResearchGrant #ExploreHT #Biomarkers #Protavio

Catch the highlights from Hellenic Cancer Federation | ELLOK’s 2nd Synergies Forum on Cancer, where our co‑founder and NTUA professor, Dr Leonidas Alexopoulos , outlined how Protavio’s multiplex protein diagnostics and AI‑guided biomarker discovery contribute in overcoming socioeconomic screening barriers and moving cancer care from treatment to true prevention. The forum also celebrated ELLOK’s new role as Greece’s National Cancer Mission Hub within the EU‑funded ECHoS programme, a catalyst uniting stakeholders to advance Europe’s Beating Cancer Plan. 🔗 Read the full recap and see how national and EU partners are joining forces to bend the cancer curve: https://lnkd.in/dumc8jFk #ELLOK #SynergiesForum #EarlyDetection #BiomarkerDiscovery #IVD #CancerResearch #HealthInnovation #MissionCancer #Protavio

On Tuesday, July 1st 2025, NTUA Professor and Protavio’s co-founder Leonidas Alexopoulos will speak at the 2nd Synergies Forum on Cancer – Policy, Research & Funding Strategies. Organised by the Hellenic Cancer Federation | ELLOK, the event will include focused sessions on prevention, precision therapies, data‑driven care and sustainable financing, and participants will map the actions and partnerships needed to modernise every step of the cancer pathway, from prevention to survivorship. In the “Prolamvano: Investing in Prevention – Strengthening Public Health” panel Prof. Alexopoulos will share his vision on translating research ideas to novel routine blood tests for early cancer detection. Join us in this open-to-public event on site or catch the live‑stream (EN/GR) to explore how these innovations can shift the needle from treatment to true prevention, delivering real‑world impact for patients and health‑care systems alike. #ELLOK #CancerResearch #HealthInnovation #SynergiesForum #EUHealth #MissionCancer #PrecisionMedicine #EarlyDetection  #Protavio